[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-patients":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100621587","pharmacometric-modeling-of-a-hospital-preparation-100621587",false,"NCT07372560","Pharmacometric Modeling of a Hospital Preparation","Pharmacometric Modeling of a Hospital Preparation of Nicardipine Hydrochloride Oral Solution at 2 mg\u002FmL in Hypertensive Patients in Pediatric Hematology-oncology","PEDIATENS","Inclusion Criteria:\n\n* Patients aged 1 to 15 years, male or female.\n* Patients followed in pediatric hematology-oncology.\n* Patients with a central venous catheter as part of their initial care and available for blood sampling.\n* Patients with a prescription for oral nicardipine (oral solution) whose formulation and\u002For dosage is\u002Fare not compatible with the commercial form of Loxen® 20 mg, requiring preparation.\n* Patients requiring oral administration of nicardipine every 8 hours (initial prescription or renewal).\n* Patients covered by a social security scheme.\n* Parents\u002Fguardians informed of the study and not objecting to their child's participation\n* For minors old enough to understand: patients who have not objected to the research.\n\nExclusion Criteria:\n\n* Patient n'ayant pas un schéma d'administration toutes les 8 heures.\n* Hypersensibilité à la substance active.\n* Antécédent d'allergie à l'un des excipients (polysorbate 80, hypromellose, saccharine sodique, sorbate de potassium, acide citrique, citrate de sodium, saccharose).\n* Refus de participation de l'enfant, des parents ou du représentant légal.\n* Inclusion de l'enfant dans un autre essai clinique, si des prélèvements sanguins supplémentaires sont également prévus, dans un délai de 7 jours.","ALL","1 Year","15 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","Pediatric prescribers are very often faced with a lack of suitable therapies, particularly oral ones. This represents a major public health problem and necessitates adjustments to dosage or pharmaceutical form using medications marketed for adults, some of which contain excipients that may be harmful to children. This creates risks of dilution errors, administration errors, and the occurrence of adverse effects. Hospital pharmacy technicians are called upon daily to provide appropriate treatment for children. However, although this activity is authorized (Public Health Code, Good Preparation Practices), pharmacokinetic\u002Fpharmacodynamic studies on these preparations are only exceptionally carried out. Indeed, only stability studies are required to determine the expiration date of the preparation. Thus, prescribers are left without the necessary information to choose the dosage and administration schedule. Pediatric dosages are extrapolated from those for adults without any certainty of the treatment's effectiveness.",[26],"Hypertensive Patients",[28,29],"Pharmacometric modeling","hématologie-oncologie pédiatrique","NOT_YET_RECRUITING","2026-01-19",{"date":33,"type":34},"2026-01-28","ACTUAL",{"date":36,"type":22},"2026-03-01",{"date":38,"type":22},"2028-06-01",{"name":40,"class":41},"University Hospital, Rouen","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100617391","handgrip-exercise-versus-walking-on-blood-pressure-100617391","NCT07318012","Handgrip Exercise Versus Walking on Blood Pressure","Impact of Isometric Handgrip Exercise Versus Walking on Blood Pressure: A Comparative Research Approach","Inclusion Criteria:\n\nstage 1 hypertension Medically stable\n\n* Able to understand and follow instructions\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* • Stage 2 hypertension\n\n  * Recent cardiovascular events\n  * Uncontrolled diabetes mellitus\n  * Severe orthopedic limitations\n  * Neurological disorders\n  * Pregnancy\n  * Recent changes in antihypertensive medication (within 3 months)\n  * Severe cardiac arrhythmias","20 Years","60 Years",{"count":53,"type":22},99,"INTERVENTIONAL",[56],"NA","The goal of this clinical study is to compare the effectiveness of isometric handgrip exercise versus walking exercise in improving blood pressure among hypertensive patients. The main question is Which of two exercise (Isometric Handgrip Exercise versus Walking Exercise) will be more effective in improvement Blood Pressure",[26],"2026-01-04",{"date":61,"type":34},"2026-01-07",{"date":63,"type":22},"2025-12-20",{"date":65,"type":22},"2026-04",{"name":67,"class":41},"Mansoura University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":54,"phases":77,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":42},"100570818","phase-1-effect-of-dexmedetomidine-on-hemodynamic-response-to-endotracheal-intubation-in-hypertensive-patients-100570818","NCT06712186","Effect of Dexmedetomidine on Hemodynamic Response to Endotracheal Intubation in Hypertensive Patients","Title: the Effects of Dexmedetomidine on Hemodynamic Responses to Endotracheal Intubation in Hypertensive Patients Undergoing Surgery","Inclusion Criteria:\n\n* ASA Grade II\n* Age \\> 60 years\n* Elective surgical procedures under GA.\n* All patients with a diagnosis of hypertension for 6 months or more and undergoing treatment with antihypertensive medications.\n\nExclusion Criteria:\n\n* Patient refusal\n* ASA Grade III and IV\n* Severely Hypovolemic state\n* Emergency surgeries\n* Body weight more than 20% of ideal body weight.\n* Patients with known or unanticipated difficult intubation and those requiring more than 15 sec or two attempts at laryngoscopy\n* Allergic to dexmedetomidine\n* Non complaint hypertensive patients\n* Patients with uncontrolled hypertension.",{"count":76,"type":22},60,[78,79],"PHASE1","PHASE2","Dexmedetomidine, an alpha-2 adrenergic agonist, has been shown to provide several benefits during endotracheal intubation:\n\n1. \\_Reduced anxiety and stress\\_: Dexmedetomidine's anxiolytic and sedative effects help reduce anxiety and stress associated with endotracheal intubation.\n2. \\_Improved intubating conditions\\_: Dexmedetomidine can improve intubating conditions by reducing the incidence of coughing, bucking, and laryngospasm.\n3. \\_Decreased hemodynamic responses\\_: Dexmedetomidine can attenuate the hemodynamic responses to intubation, including tachycardia, hypertension, and increased cardiac output.\n4. \\_Increased ease of intubation\\_: Dexmedetomidine can facilitate smoother and easier intubation by reducing the need for additional anesthetics or muscle relaxants.\n\nThe physiological responses to dexmedetomidine during intubation include:\n\n1. \\_Decreased heart rate\\_: Dexmedetomidine can cause a decrease in heart rate due to its effects on the sympathetic nervous system.\n2. \\_Decreased blood pressure\\_: Dexmedetomidine can also cause a decrease in blood pressure due to its vasodilatory effects.\n3. \\_Increased sedation\\_: Dexmedetomidine's sedative effects can help reduce anxiety and stress during intubation.\n4. \\_Reduced respiratory rate\\_: Dexmedetomidine can cause a decrease in respiratory rate due to its effects on the respiratory centers in the brain.\n\nThe clinical benefits of dexmedetomidine during intubation include:\n\n1. \\_Improved patient comfort\\_: Dexmedetomidine's sedative and anxiolytic effects can improve patient comfort during intubation.\n2. \\_Reduced need for additional anesthetics\\_: Dexmedetomidine can reduce the need for additional anesthetics or muscle relaxants during intubation.\n3. \\_Decreased risk of complications\\_: Dexmedetomidine's effects on hemodynamic responses and respiratory rate can decrease the risk of complications during intubation.",[82,26,83,84,85],"Elective Surgical Patient","Blood Pressure","Hypertensive Elderly Patients","Anxiolytic",[87,88,89,90,91,92,93,94,95,96,85],"Laryngoscopy","Dexmedetomidine","Hemodynamic Response","Endotracheal intubation","Pressor response","Hypertension","Intubation","General anesthesia","a 2 agonist","Sedative","RECRUITING","2024-12-06",{"date":100,"type":34},"2024-12-11",{"date":102,"type":34},"2024-06-22",{"date":104,"type":22},"2024-12-01",{"name":106,"class":41},"Liaquat National Hospital & Medical College"]